Genentech Bid To Gain Full Approval For Avastin On Amassed PFS Data Gets July ODAC Hearing
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche division also seeks approval for bevacizumab in new combinations based on AVADO and RIBBON-1 trial results, but the question remains whether the progression-free survival endpoint used in all the trials is sufficient for full approval.
You may also be interested in...
Avastin's Last Hope For Breast Cancer Claim May Be Subpopulations
FDA advisory committee votes to remove the breast cancer treatment indication from the Genentech drug's label after failed confirmatory trial, but two more studies are on their way.
Avastin's Last Hope For Breast Cancer Claim May Be Subpopulations
FDA advisory committee votes to remove the breast cancer treatment indication from the Genentech drug's label after failed confirmatory trial, but two more studies are on their way.
Avastin Bid For Full Approval In Metastatic Breast Cancer May Require Another Trial
FDA says Roche/Genentech's follow-up studies did not produce clinically meaningful results using the progression-free survival endpoint.